{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:11Z","timestamp":1791896471174,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"crossref","award":["ZK2012A05"],"award-info":[{"award-number":["ZK2012A05"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bbrc.2014.12.019","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T19:46:52Z","timestamp":1418327212000},"page":"821-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK\/ERK inhibitor AZD-6244"],"prefix":"10.1016","volume":"456","author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ping","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2014.12.019_b0005","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2014","key":"10.1016\/j.bbrc.2014.12.019_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2014.12.019_b0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrgastro.2010.214","article-title":"Pancreatic cancer in 2010: new insights for early intervention and detection","volume":"8","author":"Costello","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2014.12.019_b0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2014.12.019_b0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","article-title":"KRAS: feeding pancreatic cancer proliferation","volume":"39","author":"Bryant","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbrc.2014.12.019_b0030","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","article-title":"Oncogenic KRAS signalling in pancreatic cancer","volume":"111","author":"Eser","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2014.12.019_b0035","article-title":"Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer","author":"Alagesan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2014.12.019_b0040","doi-asserted-by":"crossref","first-page":"e44146","DOI":"10.1371\/journal.pone.0044146","article-title":"K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo","volume":"7","author":"Hofmann","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbrc.2014.12.019_b0045","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-08-2954","article-title":"In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase 1\/2 kinase","volume":"15","author":"Chung","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2014.12.019_b0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbalip.2008.06.002","article-title":"Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate","volume":"1781","author":"Mao","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2014.12.019_b0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2174\/157489211796957838","article-title":"Ceramide in chemotherapy of tumors","volume":"6","author":"Dimanche-Boitrel","year":"2011","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.bbrc.2014.12.019_b0060","article-title":"Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death","author":"Mullen","year":"2011","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bbrc.2014.12.019_b0065","article-title":"Targeting the ceramide system in cancer","author":"Henry","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2014.12.019_b0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-2275(20)38673-9","article-title":"Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase","volume":"28","author":"Inokuchi","year":"1987","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2014.12.019_b0075","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.fob.2014.08.005","article-title":"ROS-dependent prostate apoptosis response-4 (Par-4) up-regulation and ceramide generation are the prime signaling events associated with curcumin-induced autophagic cell death in human malignant glioma","volume":"4","author":"Thayyullathil","year":"2014","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bbrc.2014.12.019_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2011.05.156","article-title":"Glutathione selectively inhibits Doxorubicin induced phosphorylation of p53Ser(1)(5), caspase dependent ceramide production and apoptosis in human leukemic cells","volume":"411","author":"Thayyullathil","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2014.12.019_b0085","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0022-2275(20)42059-0","article-title":"Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis, and the synergistic action of an inhibitor of microsomal monooxygenase","volume":"32","author":"Shukla","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2014.12.019_b0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11010-011-1086-9","article-title":"1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K\/AKT activation","volume":"361","author":"Yu","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2014.12.019_b0095","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1096\/fj.10-180190","article-title":"Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis","volume":"25","author":"Huang","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2014.12.019_b0100","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.2741\/A380","article-title":"Treatment of advanced and metastatic pancreatic cancer","volume":"3","author":"Blaszkowsky","year":"1998","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bbrc.2014.12.019_b0105","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1053\/j.seminoncol.2007.01.006","article-title":"Treatment of advanced pancreatic cancer","volume":"34","author":"Ducreux","year":"2007","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbrc.2014.12.019_b0110","first-page":"303","article-title":"KRAS in pancreatic cancer","volume":"15","author":"Agarwal","year":"2014","journal-title":"JOP"},{"key":"10.1016\/j.bbrc.2014.12.019_b0115","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.4161\/cbt.8.20.9430","article-title":"Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models","volume":"8","author":"Chang","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbrc.2014.12.019_b0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/1535-7163.MCT-05-0457","article-title":"PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy","volume":"5","author":"Dijkhuis","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2014.12.019_b0125","first-page":"407","article-title":"Kras as a key oncogene and therapeutic target in pancreatic cancer","volume":"4","author":"Collins","year":"2013","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrc.2014.12.019_b0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00535-008-2226-1","article-title":"Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside","volume":"43","author":"Furukawa","year":"2008","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2014.12.019_b0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/187152011795677382","article-title":"Targeting phosphoinositide 3-kinase pathways in pancreatic cancer \u2013 from molecular signalling to clinical trials","volume":"11","author":"Falasca","year":"2011","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bbrc.2014.12.019_b0140","doi-asserted-by":"crossref","first-page":"e77243","DOI":"10.1371\/journal.pone.0077243","article-title":"Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbrc.2014.12.019_b0145","doi-asserted-by":"crossref","first-page":"16568","DOI":"10.1074\/jbc.273.26.16568","article-title":"Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis","volume":"273","author":"Zhou","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2014.12.019_b0150","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbrc.2012.04.012","article-title":"Increasing ceramides sensitizes genistein-induced melanoma cell apoptosis and growth inhibition","volume":"421","author":"Ji","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2014.12.019_b0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14021846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14021846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T08:35:19Z","timestamp":1650789319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X14021846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0006291X14021846"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.12.019","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK\/ERK inhibitor AZD-6244","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}